Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer.

Literature DB >> 8645586

WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer.

Abstract

Mutations in the WAF1/CIP1 gene were not found in 36 ovarian carcinomas, including tumours with loss of heterozygosity at the WAF1/CIP1 locus and/or lacking p53 mutations. In addition, no association was demonstrable between a polymorphism in a conserved region of the WAF1/CIP1 gene and ovarian carcinoma.

Entities: Disease Gene

Mesh：

Substances：

Year: 1996 PMID： 8645586 PMCID： PMC2074480 DOI： 10.1038/bjc.1996.265

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

18 in total

1. Human epithelial ovarian cancer allelotype.

Authors: W Cliby; S Ritland; L Hartmann; M Dodson; K C Halling; G Keeney; K C Podratz; R B Jenkins
Journal: Cancer Res Date: 1993-05-15 Impact factor: 12.701

2. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus.

Authors: M K Dodson; W A Cliby; H J Xu; K A DeLacey; S X Hu; G L Keeney; J Li; K C Podratz; R B Jenkins; W F Benedict
Journal: Cancer Res Date: 1994-02-01 Impact factor: 12.701

3. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression.

Authors: T M Kim; W F Benedict; H J Xu; S X Hu; J Gosewehr; M Velicescu; E Yin; J Zheng; G D'Ablaing; L Dubeau
Journal: Cancer Res Date: 1994-02-01 Impact factor: 12.701

Review 4. p53 mutations in human cancers.

Authors: M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal: Science Date: 1991-07-05 Impact factor: 47.728

2. p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas.

Authors: S Mousses; N Gokgoz; J S Wunder; H Ozcelik; S Bull; R S Bell; I L Andrulis
Journal: Br J Cancer Date: 2001-06-15 Impact factor: 7.640

Review 3. p21 in Cancer Research.

Authors: Bahar Shamloo; Sinem Usluer
Journal: Cancers (Basel) Date: 2019-08-14 Impact factor: 6.639

3 in total

WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer.

1. Human epithelial ovarian cancer allelotype.

2. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus.

3. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression.

Review 4. p53 mutations in human cancers.

5. A cell cycle regulator potentially involved in genesis of many tumor types.

6. p21 is a universal inhibitor of cyclin kinases.

7. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.

8. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas.

9. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

10. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

1. P21WAF1/Cip1 gene expression in primary human hepatocellular carcinoma and its relationship with P53 gene mutation.

2. p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas.

Review 3. p21 in Cancer Research.